4 results about "Sialidase activity" patented technology

The present invention relates to a method for producing a sialylated glycosphingolipid, comprising the steps of:-providing a glycosphingolipid, a sialic acid donor and an enzyme having transsialidase activity,-mixing the glycosphingolipid with the sialic acid donor in the presence of the enzyme having transsialidase activity, the sialylated glycosphingolipid is a sialylated glycosphingolipid, and wherein the sialic acid donor is 3 '-sialylated lactose.

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity.

Provided are: a biomarker for determining the stress level, which is for determining the stress level suffered by a subject by a non-invasive and simple method; a method for detecting the biomarker; a method for collecting data including the detection method; and a kit for determining the stress level. The above-mentioned purpose can be achieved by using, as a biomarker, sialidase activity of bacteria from a sample obtained from a subject. The sample is preferably excrement and / or the subject is preferably human.